… ) or GP (gemcitabine 1250 mg/m 2 iv days 1 and 8 plus cisplatin 75 mg/m 2 iv day 1, every
3 weeks, for up to four cycles). Patients were stratified by EGFR mutation type, ECOG PS, …

… and cisplatin for first-line treatment of patients with EGFR mutation-… We compared afatinib
with gemcitabine and cisplatin—a … patients with EGFR mutation-positive advanced NSCLC. …

… EGFR mutations in CTONG 1103, which differed from methods used previously. However,
the EGFR mutation … lower ORR may not be related to the EGFR mutation detection method. …

… the Therascreen EGFR 29 kit (Qiagen, Manchester, UK). Eligible patients were randomly
assigned to receive afatinib or gemcitabine/ cisplatin in a 2:1 ratio, stratified by EGFR mutation (…

… EGFR (ErbB1), HER2 (ErbB2) and ErbB4. A was superior to first-line pemetrexed/cisplatin in
a global phase III trial (LUX-Lung 3) in EGFR M… of first-line A with GC in EGFR M+ Asian pts. …

… EGFR mutation status in cfDNA has been confirmed in retrospective and prospective studies.
We evaluated the correlation of EGFR mutations … of the cobas ® EGFR Mutation Test v2, the …

… We compared afatinib with gemcitabine-cisplatin in Asian patients based on the LUX-Lung
6 trial. Gemcitabine is the widely accepted and approved in combination with cisplatin for first-…

… Recently, it has been clearly shown that EGFR mutations may be a positive prognostic factor
for survival in advanced NSCLC patients treated with chemotherapy with or without erlotinib …

… EGFR mutation status detection will be performed in the central laboratory by using a
quantitative polymerase chain reaction (ADx-ARMS kit; Amoy Diagnostics, Xiamen, China). Full …

… followed by EGFR-TKI (84% crossover rate to EGFR-TKI after … with tumours harbouring
activating EGFR mutations or EML4-ALK … with activating EGFR mutations, comparing EGFR-TKI …